MYRBETRIQ™ (mirabegron)
This slideshow reviews drug information for MYRBETRIQ™ (mirabegron).Table of ContentsSlide 3: Indication, Dosage & AdministrationSlide 6: Use in Specific PopulationsSlide 8: Clinical PharmacologySlide 11: Warnings & PrecautionsSlide 14: Clinical Safety & EfficacySlide 20: Drug Storage & Supply
Patients' median bladder capacity improved from 150 to 200 mL and continence improved in nearly 90% of patients.
Mirabegron may be an effective treatment for children with idiopathic overactive bladder (OAB), according to a new study.
The prospective off-label study, by Anne-Sophie Blais, MD, CHU de Québec-Université Laval, Québec, Québec, and colleagues, recruited 58 pediatric OAB patients who had no symptom improvement with behavioral or medical treatments and/or significant side effects with at least 2 different antimuscarinic agents. The patients had a median age of 10.1 years and were on mirabegron for a median of 11.5 months. Patients’ median bladder capacity improved from 150 to 200 mL and continence improved in 52 patients (89.6%), with 13 being completely dry, the researchers reported online ahead of print in European Urology.
“Mirabegron, a novel first-in-class therapy, appeared as a safe and effective alternative for children with idiopathic OAB refractory to antimuscarinics,” the authors concluded.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.